Clover Biopharmaceuticals Ltd. (HKG: 2197), a biopharmaceutical company based in China, has announced positive preliminary results from the Phase I clinical study of its pipeline candidate SCB-1019 in the elderly population. The molecule is a respiratory syncytial virus (RSV) PreF trimeric subunit candidate vaccine.
A total of 48 subjects were enrolled in the elderly cohort, with participants receiving either SCB-1019 or a physiological saline placebo. The study results indicated that SCB-1019 significantly increased the neutralizing antibody titers against RSV-A and RSV-B in the elderly group, reaching approximately 7,900 IU/mL (an up to 8-fold increase) and approximately 46,700 IU/mL (an up to 11-fold increase), respectively. The vaccine candidate demonstrated good safety and reactogenicity profiles, comparable to the data observed in the placebo group.
SCB-1019 is a bivalent recombinant protein RSV candidate vaccine developed using Clover Bio’s innovative protein trimer Tag vaccine technology platform. As the first RSV PreF candidate vaccine to reach clinical development in China, SCB-1019 may offer immunogenicity against RSV-A and RSV-B neutralizing antibodies that is on par with or superior to other protein subunit RSV PreF vaccines, based on preliminary results.- Flcube.com
